[go: up one dir, main page]

DE60210944D1 - N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten - Google Patents

N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten

Info

Publication number
DE60210944D1
DE60210944D1 DE60210944T DE60210944T DE60210944D1 DE 60210944 D1 DE60210944 D1 DE 60210944D1 DE 60210944 T DE60210944 T DE 60210944T DE 60210944 T DE60210944 T DE 60210944T DE 60210944 D1 DE60210944 D1 DE 60210944D1
Authority
DE
Germany
Prior art keywords
nmda
nonaryl
substituted heterocyclic
nr2b antagonists
nr2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60210944T
Other languages
English (en)
Other versions
DE60210944T3 (de
DE60210944T2 (de
Inventor
F Claiborne
W Butcher
A Claremon
E Libby
J Liverton
M Munson
T Nguyen
Brian Phillips
Wayne Thompson
A Mccauley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23034191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60210944(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE60210944D1 publication Critical patent/DE60210944D1/de
Application granted granted Critical
Publication of DE60210944T2 publication Critical patent/DE60210944T2/de
Publication of DE60210944T3 publication Critical patent/DE60210944T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
DE60210944.2T 2001-02-23 2002-02-20 N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten Expired - Lifetime DE60210944T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27110001P 2001-02-23 2001-02-23
US271100P 2001-02-23
PCT/US2002/005226 WO2002068409A1 (en) 2001-02-23 2002-02-20 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EP02721105.1A EP1379520B2 (de) 2001-02-23 2002-02-20 N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten

Publications (3)

Publication Number Publication Date
DE60210944D1 true DE60210944D1 (de) 2006-06-01
DE60210944T2 DE60210944T2 (de) 2007-04-19
DE60210944T3 DE60210944T3 (de) 2015-07-23

Family

ID=23034191

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60210944.2T Expired - Lifetime DE60210944T3 (de) 2001-02-23 2002-02-20 N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten

Country Status (33)

Country Link
US (2) US7053089B2 (de)
EP (1) EP1379520B2 (de)
JP (1) JP4179879B2 (de)
KR (1) KR100849839B1 (de)
CN (1) CN100567293C (de)
AT (1) ATE324371T1 (de)
AU (1) AU2002252053B2 (de)
BG (1) BG108113A (de)
BR (1) BR0207526A (de)
CA (1) CA2438895A1 (de)
CZ (1) CZ20032258A3 (de)
DE (1) DE60210944T3 (de)
DK (1) DK1379520T3 (de)
EA (1) EA005974B1 (de)
EC (1) ECSP034744A (de)
EE (1) EE200300403A (de)
ES (1) ES2261658T3 (de)
GE (1) GEP20063741B (de)
HR (1) HRP20030669A2 (de)
HU (1) HUP0303258A3 (de)
IL (2) IL157254A0 (de)
IS (1) IS6902A (de)
MX (1) MXPA03007621A (de)
NO (1) NO20033732L (de)
NZ (1) NZ527365A (de)
PL (1) PL364625A1 (de)
PT (1) PT1379520E (de)
SI (1) SI1379520T1 (de)
SK (1) SK10542003A3 (de)
UA (1) UA75392C2 (de)
WO (1) WO2002068409A1 (de)
YU (1) YU64303A (de)
ZA (1) ZA200306159B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2449249A1 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
EP1452530A4 (de) * 2001-12-03 2005-11-30 Japan Tobacco Inc Azolverbindung und deren medizinische verwendung
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2290436T3 (es) * 2002-03-15 2008-02-16 Ciba Specialty Chemicals Holding Inc. Uso de 4-aminopiridinas para el tratamiento antimicrobiano de superficies.
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1502916A4 (de) 2002-04-16 2006-05-31 Teijin Ltd Piperidinderivate mit ccr3-antagonismus
JP4429738B2 (ja) 2002-04-25 2010-03-10 帝人株式会社 Ｃｃｒ３拮抗作用を有する４，４−二置換ピペリジン誘導体
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
JP2004315511A (ja) * 2003-03-31 2004-11-11 Taisho Pharmaceut Co Ltd Ｍｃｈ受容体アンタゴニスト
US7592360B2 (en) 2003-06-04 2009-09-22 Merck & Co., Inc. 3-fluoro-piperidines as NMDA/NR2B antagonists
PL1648882T3 (pl) * 2003-06-04 2008-12-31 Merck & Co Inc 3-Fluoro-piperydyny jako antagoniści NMDA/NR2B
JP4886511B2 (ja) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物による自己免疫疾患の治療または予防方法
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1713781B1 (de) 2004-02-03 2008-11-05 AstraZeneca AB Chinazolinderivate
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
CN1993363A (zh) * 2004-08-03 2007-07-04 默克公司 1,3－二取代的杂芳基nmda/nr2b拮抗剂
WO2006027252A1 (en) * 2004-09-10 2006-03-16 Ucb Pharma, Sa Sigma receptor ligands
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
DK1814878T3 (da) 2004-11-24 2012-05-07 Rigel Pharmaceuticals Inc Spiro-2, 4-pyrimidindiamin-forbindelser og anvendelser deraf
MX2007016508A (es) 2005-06-30 2008-03-04 Prosidion Ltd Agonistas del receptor acoplado a la proteina g.
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007071639A1 (en) * 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
EP1988077A4 (de) * 2006-02-23 2009-09-02 Shionogi & Co Nitrogene heterocyclische derivate, die mit cyclischen gruppen substituiert sind
EP2007373A4 (de) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc Hemmung der alpha-synuclein-toxizität
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2102194A1 (de) * 2006-12-08 2009-09-23 F. Hoffmann-Roche AG Substituierte pyrimidine und ihre verwendung als jnk-modulatoren
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
CN101663292A (zh) * 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
MX2009011416A (es) * 2007-04-23 2009-11-05 Janssen Pharmaceutica Nv Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
SA08290520B1 (ar) * 2007-08-22 2012-02-22 استرازينيكا ايه بي مشتقات سيكلو بروبيل أميد وتركيبات صيدلية تحتوي عليها لعلاج حالة مرضية سببها مستقبلات هيستامين h3
WO2009058261A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
CN101939316B (zh) 2008-02-07 2013-10-02 贝林格尔.英格海姆国际有限公司 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
BRPI0915834A2 (pt) 2008-07-03 2015-11-03 Janssen Pharmaceutica Nv 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
AU2009275887B2 (en) 2008-07-31 2013-06-20 Janssen Pharmaceutica Nv Piperazin-1-yl-trifluoromethyl-substituted-pyridines as fast dissociating dopamine 2 receptor antagonists
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2011102795A1 (en) 2010-02-18 2011-08-25 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
BR112012020780A2 (pt) * 2010-02-18 2016-05-03 Astrazeneca Ab forma sólida, composição farmacêutica, e, uso de uma forma sólida.
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9388140B2 (en) * 2011-03-31 2016-07-12 Bayer Intellectual Property Gmbh Substituted benzimidazoles
US8722670B2 (en) * 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
ES2627541T3 (es) 2012-04-20 2017-07-28 Ucb Pharma, S.A. Métodos para tratar la enfermedad de Parkinson
JP2016028017A (ja) * 2012-12-13 2016-02-25 大正製薬株式会社 フッ素置換ピペリジン化合物
JP2017001954A (ja) * 2013-11-08 2017-01-05 石原産業株式会社 含窒素飽和複素環化合物
WO2015182724A1 (ja) * 2014-05-28 2015-12-03 トーアエイヨー株式会社 置換トロパン誘導体
AU2015271719A1 (en) * 2014-06-04 2016-12-01 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
WO2016044323A1 (en) 2014-09-15 2016-03-24 Rugen Holdings (Cayman) Limited Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
EP3253761A4 (de) 2015-02-04 2018-06-20 Rugen Holdings (Cayman) Limited 3,3-difluor-piperidinderivate als nr2b-nmda-rezeptorantagonisten
AU2016260784B2 (en) 2015-05-11 2020-03-12 Basf Se Process for preparing 4-amino-pyridazines
RU2735277C2 (ru) 2015-06-01 2020-10-29 Руджен Холдингс (Кайман) Лимитед 3,3-дифторпиперидинкарбаматные гетероциклические соединения в качестве антагонистов nr2b nmda-рецептора
WO2018098128A1 (en) 2016-11-22 2018-05-31 Rugen Holdings (Cayman) Limited Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
EP3589632B1 (de) * 2018-02-23 2020-09-23 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Neuartige inhibitoren von bakteriellen glutaminylcyclasen zur verwendung in der behandlung von parodontalen und verwandten erkrankungen
WO2025113518A1 (zh) * 2023-11-28 2025-06-05 成都地奥制药集团有限公司 一种含氮杂环化合物、其制备方法及应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL265777A (de) * 1960-06-09
DE2341965C3 (de) 1973-08-20 1979-01-25 C.H. Boehringer Sohn, 6507 Ingelheim 4- [N- (o-PyridyD- N-acyl] -aminolphenäthylpiperidine, Verfahren zu deren Herstellung sowie deren Verwendung bei der Bekämpfung von Schmerzzuständen
US4197304A (en) * 1975-09-23 1980-04-08 Janssen Pharmaceutica N.V. N-Aryl-N-(1-L-4-piperidinyl)-arylacetamides
EP0126087A1 (de) * 1982-09-24 1984-11-28 Beecham Group Plc Amino-azabicycloalkyl-derivate als dopamin-antagonisten
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
EP0554247B1 (de) 1990-05-10 2000-04-26 Pfizer Inc. Neuroprotective indolone und verwandte derivate
US5189036A (en) 1990-06-20 1993-02-23 Schering Ag Imidazolylbenzoyl substituted heterocycles
DE9290042U1 (de) 1991-04-18 1993-12-16 Pfizer Inc., New York, N.Y. Pro-Arzneimittelester von phenolischen 2-Piperidino-1-alkanolen
HUT70528A (en) 1991-07-17 1995-10-30 Pfizer 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents and process for production thereof
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
US5436255A (en) 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1994014776A2 (en) 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0687249A1 (de) 1993-03-03 1995-12-20 Eli Lilly And Company Balanoide als proteinkinase c inhibitoren
CA2156836A1 (en) 1993-03-18 1994-09-29 Janusz Jozef Kulagowski Benzimidazole derivatives
AU3138595A (en) 1994-07-20 1996-02-16 Acea Pharmaceuticals, Inc. Haloperidol analogs and the use thereof
US5661161A (en) 1994-09-29 1997-08-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0742208A1 (de) 1995-05-05 1996-11-13 Grelan Pharmaceutical Co., Ltd. 2-Ureido-benzamid-Derivate
DK0828513T3 (da) 1995-05-26 2004-04-13 Pfizer Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
EP0771779B1 (de) 1995-11-06 2002-05-02 Kuraray Co., Ltd. Verfahren zur Herstellung von Acetalen
DE19541264A1 (de) 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
ZA9610745B (en) † 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
FR2744449B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
EP0787493A1 (de) 1996-02-03 1997-08-06 F. Hoffmann-La Roche Ag Tetrahydroisochinolin-Derivate
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
WO1997045119A1 (en) 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
BR9710570A (pt) 1996-07-25 2005-06-28 Biogen Inc Inibidor de adesão de células
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0846683B1 (de) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxypiperidinderivate
FR2758328B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles amines aromatiques derivees d'amines cycliques utiles comme medicaments
FR2758327B1 (fr) 1997-01-15 1999-04-02 Pf Medicament Nouvelles arylpiperazines derivees de piperidine
IT1291569B1 (it) 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
AU1415099A (en) 1997-11-18 1999-06-07 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
DE19815026A1 (de) * 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
PE20000728A1 (es) 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE69931975T2 (de) 1998-08-07 2006-10-05 Applied Research Systems Ars Holding N.V. FSH Mimetika zur Behandlung von Infertilität
DE19838300A1 (de) 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
PL351279A1 (en) 1999-04-13 2003-04-07 Abbott Gmbh & Co Kg Integrin receptor ligands
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds

Also Published As

Publication number Publication date
IS6902A (is) 2003-07-31
SI1379520T1 (sl) 2006-08-31
ECSP034744A (es) 2003-10-28
US7053089B2 (en) 2006-05-30
DK1379520T3 (da) 2006-08-21
BG108113A (bg) 2005-04-30
GEP20063741B (en) 2006-02-10
NZ527365A (en) 2005-08-26
CN1503793A (zh) 2004-06-09
DE60210944T3 (de) 2015-07-23
CN100567293C (zh) 2009-12-09
AU2002252053C1 (en) 2002-09-12
IL157254A0 (en) 2004-02-19
BR0207526A (pt) 2004-03-09
EA005974B1 (ru) 2005-08-25
UA75392C2 (en) 2006-04-17
HUP0303258A3 (en) 2004-06-28
KR100849839B1 (ko) 2008-08-01
EE200300403A (et) 2003-12-15
AU2002252053B2 (en) 2006-09-14
CA2438895A1 (en) 2002-09-06
MXPA03007621A (es) 2003-12-04
NO20033732D0 (no) 2003-08-22
SK10542003A3 (sk) 2004-03-02
ATE324371T1 (de) 2006-05-15
EP1379520A1 (de) 2004-01-14
US7217716B2 (en) 2007-05-15
EP1379520B2 (de) 2014-04-09
KR20030076703A (ko) 2003-09-26
HRP20030669A2 (en) 2005-06-30
CZ20032258A3 (cs) 2004-01-14
IL157254A (en) 2008-11-26
WO2002068409A1 (en) 2002-09-06
EP1379520B1 (de) 2006-04-26
US20040209889A1 (en) 2004-10-21
YU64303A (sh) 2006-05-25
JP2004524314A (ja) 2004-08-12
DE60210944T2 (de) 2007-04-19
NO20033732L (no) 2003-10-22
PT1379520E (pt) 2006-08-31
EA200300919A1 (ru) 2004-02-26
PL364625A1 (en) 2004-12-13
JP4179879B2 (ja) 2008-11-12
US20020165241A1 (en) 2002-11-07
ZA200306159B (en) 2004-07-05
ES2261658T3 (es) 2006-11-16
HUP0303258A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
NO20041504L (no) Lactamderivater som antagonister for humane 11CBY reseptorer.
ATE440603T1 (de) 8-hydroxychinolinderivate
ATE399770T1 (de) Tachykininrezeptorantagonisten
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
ATE377589T1 (de) 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
DE60302157D1 (de) Opioidrezeptorantagonisten
GB0308201D0 (en) Novel compounds
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
NO20052182L (no) Nye forbindelser
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
SE0102057D0 (sv) New Salts I
SE0102058D0 (sv) New Salts II
ATE491709T1 (de) Pyrrolidinohydrochinazoline
ATE338046T1 (de) 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza- cyclopenta(a)naphthalenyl derivate mit antipsychotischer aktivität

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1379520

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 1379520

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213